EC approves Regeneron’s Libtayo as monotherapy for advanced cervical cancer
Libtayo is now indicated for the treatment of four cancer types in the European Union
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Nov 22
Libtayo is now indicated for the treatment of four cancer types in the European Union
21 Nov 22
The expanded authorisation in Canada was based on the findings of a phase 2 clinical trial held in…
18 Nov 22
The EC approval for Enjaymo was driven by the findings from the CADENZA and CARDINAL phase 3 clinical…
17 Nov 22
The FDA advisory committee voted nine to four in favour of XPHOZAH as monotherapy and ten to two…
16 Nov 22
Indivior will acquire Opiant at a price of $20 per share, for around $145m, in addition to $8…
16 Nov 22
The new Amazon Clinic will be accessible initially in 32 states and will offer virtual care for various…
15 Nov 22
The promising candidates emerging from the research collaboration will move on to further development with the therapeutics discovery…
09 Nov 22
Companies are seeing an increasing necessity to work jointly with their partners in supply and manufacturing to ensure…
08 Nov 22
The combined company will leverage VillageMD’s expertise in value-based care and Summit Health-CityMD’s expertise in multispecialty, connected care…
07 Nov 22
Doubling down on innovation and technology, Arab Health will also host the second edition of the Future Health…